Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups by Erkan Ozcan, Ivo Gokmen, Fahri Akgul, Fatma Akdag Kahvecioglu, Abdussamet Celebi, Osman Kostek, Ilhan Hacıbekiroglu, Bulent Erdogan

Get full text

Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treate... by Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali

Get full text

Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Ove... by Ozkan Alan, Tugba Akın Telli, Sinem Akbas, Selver Isik, Eyyüb Çavdar, Kubilay Karaboyun, Aysegül Merc Cetinkaya, Ferhat Ekinci, Atike Pınar Erdoğan, Mahmut Büyükşimsek, Muhammed Muhittin Er, Melek Karakurt Eryilmaz, Taliha Güçlü Kantar, Gamze Gököz Doğu, Teoman Sakalar, Ertuğrul Bayram, Ali Inal, Fatma Akdağ Kahvecioğlu, İlhan Hacibekiroğlu, Fatih Selçukbiricik, Ali Murat Tatli, Perran Fulden Yumuk

Get full text

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC by Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD

Get full text

Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Esra Aydın, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan

Get full text